Antitrust Antitrust

Chinese drugmaker Puyunhui questions SAMR's inconsistency in penalty decision at court

By Yonnex Li
  • 17 Dec 2020 01:02
  • 17 Dec 2020 03:09
Weifang Puyunhui Pharmaceutical, a Chinese supplier of raw materials for pharmaceutical products, has argued at a Beijing court that the country's competition regulator showed inconsistency in its penalty decision against the company and two other industry peers regarding allegations they collectively abused their market dominance.

The State Administration for Market Regulation, or SAMR,

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Yonnex Li

Chief Correspondent, Greater China


Yonnex has an MA in Journalism from the Chinese University of Hong Kong, after obtaining a BA in Translation at the same university. At MLex, she writes extensively on antitrust developments in the Greater China region, including investigations, court cases and merger control of international transactions. Prior to joining MLex, she worked as a reporter at the English division of the Hong Kong Economic Journal, providing coverage and analysis on China's banking sector, asset management industry as well as currency and financial reforms.

Discover MLex

Stay on top of global regulatory developments

TAKE A FREE TRIAL

Latest News